Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685784 | 0.92 | TRPV1 (0.56) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2684964 | 0.90 | TRPV1 (0.52) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2685448 | 0.90 | TRPV1 (0.56) | TRPV1TP53 | |
| SCHEMBL2686148 | 0.90 | TRPV1 (0.53) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2686538 | 0.89 | TRPV1 (0.52) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2684954 | 0.89 | TRPV1 (0.52) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2685039 | 0.89 | TRPV1 (0.54) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2685453 | 0.88 | TRPV1 (0.52) | TRPV1TP53NAMPTSMN1; SMN2NPC1 | |
| SCHEMBL2685073 | 0.88 | TRPV1 (0.53) | TRPV1TP53NAMPTRAB9A | |
| SCHEMBL2685083 | 0.87 | TRPV1 (0.53) | TRPV1TP53NAMPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | claimed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | claimed |
| EP-1775283-A1 | 3-AMINOBENAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-18 | — | — | EP | claimed |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | claimed |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1775283-A1 | 3-AMINOBENAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | TRPV1 1/4885TP53 4029/4885NAMPT 2169/4885 |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | TRPV1, TRPV6, TRPV3 | TRPV1 1/4885TP53 4243/4885NAMPT 2732/4885 |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | TRPV1 1/4885TP53 3854/4885NAMPT 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.